Thomas E. Darga

Thomas E. Darga

Auto-generated profile, based on publicly available information

Thomas E. Darga

Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL 60637, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Immunity
Verified
Journal Article
Closed access
LDLiufu Deng
Liufu Deng
HLHua Liang
Hua Liang
MXMeng Xu
Meng Xu
XYXuanming Yang
Xuanming Yang
BBByron Burnette
Byron Burnette
RWRalph Weichselbaum
Ralph Weichselbaum

2 January 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LDLiufu Deng
Liufu Deng
HLHua Liang
Hua Liang
BBByron Burnette
Byron Burnette
MBMichael Beckett
Michael Beckett
TDThomas Darga
Thomas Darga
YFYang-Xin Fu
Yang-Xin Fu
High-dose ionizing irradiation (IR) results in direct tumor cell death and augments tumor-specific immunity, which enhances tumor control both locally and distantly. Unfortunately, local relapses often occur following IR treatment, indicating that IR-induced responses are inadequate to maintain antitumor immunity. Therapeutic blockade of the T cell negative regulator programmed death–ligand 1 (PD-L1, also called B7-H1) can enhance T cell effector function when PD-L1 is expressed in chronically inflamed tissues and tumors. Here, we demonstrate that PD-L1 was upregulated in the tumor microenvironment after IR. Administration of anti–PD-L1 enhanced the efficacy of IR through a cytotoxic T cell–dependent mechanism. Concomitant with IR-mediated tumor regression, we observed that IR and anti–PD-L1 synergistically reduced the local accumulation of tumor-infiltrating myeloid-derived suppressor cells (MDSCs), which suppress T cells and alter the tumor immune microenvironment. Furthermore, activation of cytotoxic T cells with combination therapy mediated the reduction of MDSCs in tumors through the cytotoxic actions of TNF. Our data provide evidence for a close interaction between IR, T cells, and the PD-L1/PD-1 axis and establish a basis for the rational design of combination therapy with immune modulators and radiotherapy.

30 January 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NKNikolai N. Khodarev
Nikolai N. Khodarev
MBMichael Beckett
Michael Beckett
ELEdwardine Labay
Edwardine Labay
TDThomas Darga
Thomas Darga
BRBernard Roizman
Bernard Roizman
RWRalph R. Weichselbaum
Ralph R. Weichselbaum
Nu61, a radiation-resistant human tumor xenograft, was selected from a parental radiosensitive tumor SCC-61 by eight serial cycles of passage in athymic nude mice and in vivo irradiation. Replicate DNA array experiments identified 52 genes differentially expressed in nu61 tumors compared with SCC-61 tumors. Of these, 19 genes were in the IFN-signaling pathway and moreover, 25 of the 52 genes were inducible by IFN in the nu61 cell line. Among the genes involved in IFN signaling, STAT1α and STAT1β were the most highly overexpressed in nu61 compared to SCC-61. STAT1α and STAT1β cDNAs were cloned and stably transfected into SCC-61 tumor cells. Clones of SCC-61 tumor cells transfected with vectors expressing STAT1α and STAT1β demonstrated radioprotection after exposure to 3 Gy ( P < 0.038). The results indicate that radioresistance acquired during radiotherapy treatment may account for some treatment failures and demonstrate an association of acquired tumor radioresistance with up-regulation of components of the IFN-related signaling pathway.

13 December 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Yves LussierYves Lussier
Yves Lussier
HXH. Rosie Xing
H. Rosie Xing
JSJoseph K. Salama
Joseph K. Salama
NKNikolai N. Khodarev
Nikolai N. Khodarev
YHYong Huang
Yong Huang
RWRalph Weichselbaum
Ralph Weichselbaum
Cancer staging and treatment presumes a division into localized or metastatic disease. We proposed an intermediate state defined by ≤5 cumulative metastasis(es), termed oligometastases. In contrast to widespread polymetastases, oligometastatic patients may benefit from metastasis-directed local treatments. However, many patients who initially present with oligometastases progress to polymetastases. Predictors of progression could improve patient selection for metastasis-directed therapy. Here, we identified patterns of microRNA expression of tumor samples from oligometastatic patients treated with high-dose radiotherapy. Patients who failed to develop polymetastases are characterized by unique prioritized features of a microRNA classifier that includes the microRNA-200 family. We created an oligometastatic-polymetastatic xenograft model in which the patient-derived microRNAs discriminated between the two metastatic outcomes. MicroRNA-200c enhancement in an oligometastatic cell line resulted in polymetastatic progression. These results demonstrate a biological basis for oligometastases and a potential for using microRNA expression to identify patients most likely to remain oligometastatic after metastasis-directed treatment.

10 December 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Yves LussierYves Lussier
Yves Lussier
NKNikolai N. Khodarev
Nikolai N. Khodarev
KRKelly Regan
Kelly Regan
KCKimberly Corbin
Kimberly Corbin
HLHaiquan Li
Haiquan Li
RWRalph Weichselbaum
Ralph Weichselbaum
Strategies to stage and treat cancer rely on a presumption of either localized or widespread metastatic disease. An intermediate state of metastasis termed oligometastasis(es) characterized by limited progression has been proposed. Oligometastases are amenable to treatment by surgical resection or radiotherapy. We analyzed microRNA expression patterns from lung metastasis samples of patients with ≤5 initial metastases resected with curative intent. Patients were stratified into subgroups based on their rate of metastatic progression. We prioritized microRNAs between patients with the highest and lowest rates of recurrence. We designated these as high rate of progression (HRP) and low rate of progression (LRP); the latter group included patients with no recurrences. The prioritized microRNAs distinguished HRP from LRP and were associated with rate of metastatic progression and survival in an independent validation dataset. Oligo- and poly- metastasis are distinct entities at the clinical and molecular level.

15 March 2003 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
NKNikolai N. Khodarev
Nikolai N. Khodarev
JYJianqing Yu
Jianqing Yu
ELEdwardine Labay
Edwardine Labay
TDThomas Darga
Thomas Darga
CBCharles K. Brown
Charles K. Brown
RWRalph R. Weichselbaum
Ralph R. Weichselbaum
Tumour angiogenesis is a complex process based upon a sequence of interactions between tumour cells and endothelial cells. To model tumour/endothelial-cell interactions, we co-cultured U87 human glioma cells with human umbilical vein endothelial cells (HUVECs). U87 cells induced an`activated' phenotype in HUVECs, including an increase in proliferation,migration and net-like formation. Activation was observed in co-cultures where cells were in direct contact and physically separated, suggesting an important role for soluble factor(s) in the phenotypic and genotypic changes observed. Expressional profiling of tumour-activated endothelial cells was evaluated using cDNA arrays and confirmed by quantitative PCR. Matching pairs of receptors/ligands were found to be coordinately expressed, including TGFβRII with TGFβ3, FGFRII and cysteine-rich fibroblast growth factor receptor (CRF-1) with FGF7 and FGF12, CCR1, CCR3, CCR5 with RANTES and calcitronin receptor-like gene (CALCRL) with adrenomedullin. Consistent with cDNA array data, immunohistochemical staining of expressed proteins revealed the upregulation of Tie-2 receptor in vitro and in vivo. Our data suggest that tumour-induced activation of quiescent endothelial cells involves the expression of angiogenesis-related receptors and the induction of autocrine growth loops. We suggest that tumour cells release growth factors that induce endothelial cells to express specific ligands and their cognate receptors coordinately.